Medtronic study shows benefits of TAVR for aortic stenosis

Medtronic has announced the findings of a new clinical trial called SURTAVI, highlighting the benefits of its CoreValve transcatheter aortic valve replacement (TAVR) platform.

The study evaluated Medtronic's CoreValve system and CoreValve Evolut R system compared to open-heart surgery in the treatment of intermediate-risk severe aortic stenosis patients after two years.

Medtronic's self-expanding TAVR platform met its primary endpoint, with rates of all-cause mortality or disabling stroke at two years shown to be similar to surgical aortic valve replacement.

The minimally-invasive TAVR procedure also demonstrated significantly better mean aortic valve gradients at two years, with none of the patients displaying evidence of structural valve deterioration after this time.

Rhonda Robb, vice-president and general manager of Medtronic's heart valve therapies business, said: "This is a landmark trial demonstrating our commitment to generating clinical evidence to support the expansion of global patient access to life-changing therapies such as TAVR."

The Evolut R system was granted European CE Mark approval for the treatment of intermediate-risk severe aortic stenosis patients in 2016.

With over 20 years of experience within the medical devices market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current medical device roles we have available, you can search for the latest job roles, register your details, or contact the team today.